Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women
NCT ID: NCT06564883
Last Updated: 2024-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
45 participants
INTERVENTIONAL
2025-03-01
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Vaginismus and other sexual dysfunctions related to penetration
* Users of hormonal contraceptives with lubrication loss
* Postpartum and lactational period
* Post antibacterial or antifungal therapies
* During systemic oncological treatments (chemotherapy, radiotherapy, hormone therapy)
* Climacteric (urogenital atrophy)
* Post urogynecological surgeries (correction of urinary incontinence, genital dystopias, etc.)
* Post vulvovaginal abrasive, chemical, laser, or high-frequency therapies
* Post cosmetic and genital rejuvenation therapies
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause
NCT06176820
Efficacy and Safety of a Hyaluronic Acid-Based Vaginal Moisturizer Medical Device to Ease Symptoms of Vaginal Dryness
NCT05888116
Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness
NCT01557179
Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action
NCT05644444
Assess Efficacy, Safety, and Tolerability of 8 Weeks of Vaginal Hyaluronic (V-HYAL) Gel in Peri- and Post-Menopausal Female
NCT06964646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Arm
Hyaluronic Acid will applied under recommended conditions during the period of T22 ±2 days.
0.20% sodium hyaluronate gel
Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.20% sodium hyaluronate gel
Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intact skin and mucosa in the test region;
* Participants vaccinated for COVID-19 (Corona virus Disease).
* Agreement to adhere to the study procedures and requirements and attend the institute on the day(s) and time(s) determined for the assessments;
* Ability to consent to participate in the study;
* Menopausal participants of any age, without systemic or topical hormone replacement therapy in the last 6 months
* Presenting mild to moderate vaginal dryness (≥0.5 and \<7.5) - according to the Visual Analogic Scale
* Healthy research participants, with an active sex life (at least once a week)
Exclusion Criteria
* Decompensated Diabetes Mellitus (TBD by the institute together with the sponsor);
* Immune insufficiency;
* Current use of the following topical or systemic medications: corticosteroids, immunosuppressants and antihistamines;
* Skin diseases: vitiligo, psoriasis, atopic dermatitis;
* Previous reaction to the category of the product tested;
* Other illnesses or medications that may directly interfere with the study or put the health of the research participant at risk.
* Have used vaginal moisturizing creams and/or intimate lubricants 5 days before the initial study visit;
* Have had sexual intercourse at least 48 hours before the initial study visit;
* Have been diagnosed with a urogenital or vaginal infection in the last 30 days;
* Have used topical or systemic antibiotics, antifungals, hormone-based creams or treatment for vaginal atrophy in the last 30 days.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biolab Sanus Farmaceutica
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BS-GIMM24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.